Premium
Biologics in dermatology: What does the future hold?
Author(s) -
Yavuz Cahit
Publication year - 2019
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.12932
Subject(s) - medicine , infliximab , dermatology , psoriasis , biological drugs , dermatological diseases , intensive care medicine , disease , pathology
As the first dermatological biological treatment, infliximab was first used in the treatment of psoriasis in 2001. Since that time many biological agents have come into use for dermatological diseases and developments in this area are still ongoing. The most important feature of biological treatments is that the treatment must be target directed. In the light of technological developments, the concept has emerged of treatment directed to a patient‐specific target.